AR121675A1 - 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 - Google Patents
3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52Info
- Publication number
- AR121675A1 AR121675A1 ARP210100766A ARP210100766A AR121675A1 AR 121675 A1 AR121675 A1 AR 121675A1 AR P210100766 A ARP210100766 A AR P210100766A AR P210100766 A ARP210100766 A AR P210100766A AR 121675 A1 AR121675 A1 AR 121675A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- following
- phenoxiazethidin
- pyrazines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de 3-fenoxiazetidin-1-il-pirazina con actividad agonista de GPR52, una composición farmacéutica que contiene al menos uno de éstos compuestos y el empleo de los mismos para el tratamiento de trastornos del SNC tales como esquizofrenia, enfermedad de Parkinson y enfermedad de Alzheimer. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque A se selecciona del grupo Aᵃ que consiste en lo siguiente: un resto de fórmula (2) y (3); R¹ se selecciona del grupo R¹ᵃ que consiste en lo siguiente H- y F-; R² se selecciona del grupo R²ᵃ que consiste en lo siguiente H- y F-; R³ se selecciona del grupo R³ᵃ que consiste en lo siguiente halógeno, F₂HCO-, F₃CO-, F₂HC- y F₃C-; R⁴ se selecciona del grupo R⁴ᵃ que consiste en lo siguiente H- y alquilo C₁₋₃, donde el grupo alquilo C₁₋₃ mencionado anteriormente puede estar opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente del grupo que consiste en flúor; o una sal de este.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063001640P | 2020-03-30 | 2020-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121675A1 true AR121675A1 (es) | 2022-06-29 |
Family
ID=75362607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100766A AR121675A1 (es) | 2020-03-30 | 2021-03-29 | 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11780827B2 (es) |
EP (1) | EP4126850B1 (es) |
JP (1) | JP2023522307A (es) |
KR (1) | KR20220161454A (es) |
CN (1) | CN115697997B (es) |
AR (1) | AR121675A1 (es) |
AU (1) | AU2021250303A1 (es) |
BR (1) | BR112022018996A2 (es) |
CA (1) | CA3176265A1 (es) |
CO (1) | CO2022014886A2 (es) |
CR (1) | CR20220554A (es) |
DO (1) | DOP2022000203A (es) |
EC (1) | ECSP22080683A (es) |
IL (1) | IL296823A (es) |
MX (1) | MX2022012067A (es) |
PE (1) | PE20221918A1 (es) |
TW (1) | TW202204343A (es) |
WO (1) | WO2021198149A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4402138A1 (en) | 2021-09-14 | 2024-07-24 | Boehringer Ingelheim International GmbH | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110009421A1 (en) * | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
JPWO2011078360A1 (ja) | 2009-12-24 | 2013-05-09 | 武田薬品工業株式会社 | アミド化合物 |
JPWO2011093352A1 (ja) | 2010-01-27 | 2013-06-06 | 武田薬品工業株式会社 | チアゾール誘導体 |
WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
WO2012020738A1 (ja) | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
MX2017013853A (es) | 2015-04-29 | 2018-06-07 | Arena Pharm Inc | 1-heteroarl-indolin-4-carboxamidas como moduladores de gpr52 utiles para el tratamiento o prevencion de trastornos relacionados a las mismas. |
CN108348528A (zh) * | 2015-09-17 | 2018-07-31 | 科达生物治疗公司 | 治疗神经障碍的组合物和方法 |
-
2021
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en active Application Filing
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en active Pending
- 2021-03-29 JP JP2022559709A patent/JP2023522307A/ja active Pending
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko unknown
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es unknown
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021198149A1 (en) | 2021-10-07 |
PE20221918A1 (es) | 2022-12-29 |
CR20220554A (es) | 2023-01-09 |
TW202204343A (zh) | 2022-02-01 |
ECSP22080683A (es) | 2022-11-30 |
EP4126850A1 (en) | 2023-02-08 |
CN115697997B (zh) | 2024-07-30 |
CO2022014886A2 (es) | 2022-10-31 |
JP2023522307A (ja) | 2023-05-30 |
EP4126850B1 (en) | 2024-04-17 |
CN115697997A (zh) | 2023-02-03 |
CA3176265A1 (en) | 2021-10-07 |
MX2022012067A (es) | 2022-10-13 |
AU2021250303A1 (en) | 2022-09-22 |
DOP2022000203A (es) | 2022-11-30 |
US20220356172A1 (en) | 2022-11-10 |
IL296823A (en) | 2022-11-01 |
US11780827B2 (en) | 2023-10-10 |
KR20220161454A (ko) | 2022-12-06 |
BR112022018996A2 (pt) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
AR108011A1 (es) | Moduladores receptores de estrógenos | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
BR112014025564A8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
AR101177A1 (es) | Inhibidores de la syk | |
AR108906A1 (es) | Heterociclos de biarilmetilo | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR093937A1 (es) | Compuestos quimicos | |
MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
RS53378B (en) | CONDENSED RING UNITS AND THEIR USE | |
AR076714A1 (es) | Agonistas del receptor de glucocorticoides | |
AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
CL2019000462A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional solicitud 201603258) | |
AR121675A1 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 | |
AR122096A2 (es) | Compuestos profármacos de creatina y composiciones que los comprenden | |
AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
AR061433A1 (es) | Compuestos de amida del acido 3-amino-tieno (2,3,b) piridina -2-carboxilico sustituido, procesos para su preparacion y usos de los mismos |